High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone

References

• Vose J, Neumann M, Harris M. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcome. J Clin Oncol 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, . Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474–2479.
   PubMed Web of Science ®Google Scholar
• Torizumi K, Aibata H, Yamada R, . A study on the measurement of serum thymidine kinase and its clinical significance in hematological neoplastic disorders. Kaku Igaku 1988;26:561–567.
   Google Scholar
• Gerdes J, Lemke H, Baisch H, . Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710–1715.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Stein H, Pileri S, . Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 1987;22:448–449.
   Google Scholar
• Swan F Jr, Velaquez WS, Tucker S, . A serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J ClinOncol 1989;7:1518–1527.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Whelan J, Longhurst S, . Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer 1993;67:792–797.
   PubMed Web of Science ®Google Scholar
• Jose R, Eulogio C, Antonio G, . The adjusted International Prognostic Index and β-2 microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007;92:1067–1074.
   PubMed Web of Science ®Google Scholar
• Kitagawa J, Hara T, Tsurumi H, . Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol 2009;135:53–59.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim BS, Choi CW, . Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007;18:1382–1387.
   PubMed Web of Science ®Google Scholar
• Grogan TM, Lippman SM, Spier CM, . Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157–1160.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Habermann TM, Kurtin PJ, . S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. Cancer 1995;94:1059–1064.
   Web of Science ®Google Scholar
• Reichard P, Estborn B. Utilization of deoxyribosides in the synthesis of polynucleotides. J Biol Chem 1951;188:839–846.
   PubMed Web of Science ®Google Scholar
• Kit S. Viral-associated and induced enzymes. Phamacol Ther 1979;4:501–585.
   Web of Science ®Google Scholar
• Bello LJ. Regulation of thymidine kinase synthesis in human cells. Exp Cell Res 1974;89:263–274.
   PubMed Web of Science ®Google Scholar
• Gronowitz JS, Kallamder CFR, Diderholm H, . Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 1984;33:5–12.
   PubMed Web of Science ®Google Scholar
• Hallek M, Wandeders L, Strohmeyer S, Emmerrich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;65:1–5.
   PubMed Web of Science ®Google Scholar
• Ellims PH, Eng Gan ET, Medley G, . Prognostic relevance of thymidine kinase in adult non-Hodgkin's lymphoma. Blood 1981;58:926–930.
   PubMed Web of Science ®Google Scholar
• Kallander CF, Simmonsson B, Hagberg H, . Serum deoxythymidine kinase gives prognostic information in chronic lymphoblastic leukemia. Cancer 1984;54:2450–2455.
   PubMed Web of Science ®Google Scholar
• Martinsson U, Glimelius B, Hagberg H, . Primarily asymptomatic low grade non-Hodgkin's lymphomas: predication of symptom-free survival and total survival. Eur J Haematol 1989;43:332–338.
   PubMed Web of Science ®Google Scholar
• Kallander CF, Simonsson B, Gronowitz JS, . Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphoblastic leukemia. Eur J Haematol 1987;38:331–337.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Wigren T, Lehtinen T, . Correlation between serum tumor marker levels and tumor proliferation in small cell lung cancer. TumourBiol 1988;9:287–292.
   Google Scholar
• Robb RJ. Human T-cell growth factor: purification and interaction with a cellular receptor. Lymphokine Res 1982;1:37–43.
   PubMedGoogle Scholar
• Cantrell DA, Smith KA. Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med 1983;158:1895–1911.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Kurman CC, Fritz ME, . Soluble interleukine 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172–3177.
   PubMed Web of Science ®Google Scholar
• Hagberg H, Killander A, Simmonsson B. Serum b2-microglobulin in malignant lymphoma. Cancer 1983;51:2220–2225.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Cabanillas F, McLaughlin P, . A proposal for a simple staging system for intermediate grade lymphoma based on the tumor score. Ann Oncol 1992;3:711–717.
   PubMed Web of Science ®Google Scholar
• Jagannath S. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large cell lymphoma. J Clin Oncol 1986;4:859–865.
   PubMed Web of Science ®Google Scholar
• Schneider R. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer 1980;46:139–143.
   PubMed Web of Science ®Google Scholar
• Preti HA, Cabanillas F, Talpaz M, . Prognostic value of serum interleukin-6 in diffuse large-cell lymphomas. Ann Intern Med 1997;127:186–194.
   PubMed Web of Science ®Google Scholar
• Mahmoud FA, Riveca NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250–255.
   PubMedGoogle Scholar
• Perez-Encinas M, Villamayor M, Campos A, . Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma. Haematologica 1998;83:752–754.
   PubMed Web of Science ®Google Scholar
• Miller TP, Grogan TM, Dahlberg S, . Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460–1466.
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffer B, . Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003;102:4284–4289.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Nakamine H, . Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphoma. Hematol Oncol 2008;26:152–158.
   PubMed Web of Science ®Google Scholar
• Escalon MP, Liu NS, Yang Y, . Prognostic factors and treatment of patients with T-cell non Hodgkin lymphoma. Cancer 2005;103:2091–2098.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Venturini F, Stefoni V, . Gemcitabine as single agent in peripheral T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010;21:860–863.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Chong G, Cunningham D, . Gemcitabine, cisplatin and methyprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007;92:271–272.
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chea YS, . CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T-cell lymphomas. Cancer Chemother Pharmacol 2006;58:35–39.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Hamlin PA, Portlock C, . Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remission in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007;139:425–428.
   PubMed Web of Science ®Google Scholar